CY1116925T1 - Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια - Google Patents

Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια

Info

Publication number
CY1116925T1
CY1116925T1 CY20151100824T CY151100824T CY1116925T1 CY 1116925 T1 CY1116925 T1 CY 1116925T1 CY 20151100824 T CY20151100824 T CY 20151100824T CY 151100824 T CY151100824 T CY 151100824T CY 1116925 T1 CY1116925 T1 CY 1116925T1
Authority
CY
Cyprus
Prior art keywords
relaxin
acute heart
acute
heart deficiency
education
Prior art date
Application number
CY20151100824T
Other languages
Greek (el)
English (en)
Inventor
Elaine Unemori
Sam L Teichman
Gad Cotter
Dennis R Stewart
Martha Jo Whitehouse
Original Assignee
Corthera, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera, Inc. filed Critical Corthera, Inc.
Publication of CY1116925T1 publication Critical patent/CY1116925T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20151100824T 2008-05-16 2015-09-18 Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια CY1116925T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
US16433309P 2009-03-27 2009-03-27
EP09747740.0A EP2288373B1 (en) 2008-05-16 2009-05-15 Relaxin for use in treating of dyspnea associated with acute heart failure

Publications (1)

Publication Number Publication Date
CY1116925T1 true CY1116925T1 (el) 2017-04-05

Family

ID=40834101

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100824T CY1116925T1 (el) 2008-05-16 2015-09-18 Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια

Country Status (30)

Country Link
US (7) US8053411B2 (enExample)
EP (2) EP2288373B1 (enExample)
JP (4) JP5651586B2 (enExample)
CN (3) CN103212063B (enExample)
AR (1) AR071810A1 (enExample)
AU (1) AU2009246114B2 (enExample)
BR (1) BRPI0913011A2 (enExample)
CA (1) CA2724540C (enExample)
CR (1) CR11749A (enExample)
CY (1) CY1116925T1 (enExample)
DK (1) DK2288373T3 (enExample)
EA (2) EA022948B1 (enExample)
ES (1) ES2546287T3 (enExample)
GB (2) GB2462221B (enExample)
HK (1) HK1202054A1 (enExample)
HR (1) HRP20150845T1 (enExample)
HU (1) HUE025483T2 (enExample)
IL (3) IL208992A (enExample)
MA (1) MA32389B1 (enExample)
MX (1) MX2010012450A (enExample)
MY (2) MY159803A (enExample)
NZ (3) NZ701038A (enExample)
PL (1) PL2288373T3 (enExample)
PT (1) PT2288373E (enExample)
SG (2) SG191587A1 (enExample)
SI (1) SI2288373T1 (enExample)
TW (1) TWI386202B (enExample)
UA (1) UA99953C2 (enExample)
WO (1) WO2009140659A2 (enExample)
ZA (1) ZA201007449B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140659A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating dyspnea associated with acute heart failure
MX336145B (es) * 2008-05-16 2016-01-08 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
US20130053318A1 (en) 2010-03-10 2013-02-28 Parry Laura Modulating aquaporins with relaxin
EP2601532B1 (en) * 2010-08-06 2016-01-27 Mycartis N.V. Perlecan as a biomarker for renal dysfunction
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
US9382305B2 (en) * 2011-07-01 2016-07-05 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
PT2814513T (pt) * 2012-02-14 2018-03-02 Univ California Entrega sistémica e expressão regulada de genes parácrinos para doenças cardiovasculares e outras doenças
ES2929283T3 (es) 2012-05-04 2022-11-28 Us Health Moduladores del receptor de relaxina 1
EA030354B1 (ru) * 2012-10-26 2018-07-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ уменьшения диспноэ у пациента с острой сердечной недостаточностью
US9884039B2 (en) 2013-04-05 2018-02-06 Scpharmaceuticals Inc. Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
SG11201605273XA (en) * 2014-02-03 2016-08-30 Novartis Ag Filters for infusion sets
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
BR112016028833A2 (pt) * 2014-06-13 2017-08-22 Novartis Ag uso de serelaxinaa para reduzir gdf-15
PT3387019T (pt) 2015-12-09 2022-01-14 Scripps Research Inst Proteínas de fusão de imunoglobulina de relaxina e métodos de uso
WO2017139164A1 (en) 2016-02-12 2017-08-17 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
US12403120B2 (en) 2018-12-10 2025-09-02 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
EP3906019B1 (en) 2019-01-04 2025-11-26 SQ Innovation AG Pharmaceutical compositions of furosemide
EP3906020B1 (en) 2019-01-04 2025-12-31 SQ Innovation AG Pharmaceutical compositions of torsemide and their uses
CA3128033A1 (en) 2019-01-31 2020-08-06 Scpharmaceuticals Inc. Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
AU2023332056A1 (en) 2022-08-31 2025-03-13 Relaxera Pharmazeutische Gesellschaft mbH & Co. KG Immunosuppressive medicament and method of treatment
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
EP0707650B1 (en) * 1993-06-21 2003-05-21 Genentech, Inc. Process for producing human relaxin
WO1995003822A2 (en) * 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) * 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
DE69624925T2 (de) 1995-08-15 2003-09-04 Connetics Corp., Palo Alto Verwendung von relaxin zur stimulierung der angiogenese
DE60128540T2 (de) 2000-02-09 2008-01-31 Bas Medical, Inc., San Mateo Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
WO2006075819A1 (en) * 2004-03-30 2006-07-20 Industry-Academic Cooperation Foundation, Yonsei University Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US20080077025A1 (en) * 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
AU2008273813B2 (en) 2007-07-12 2013-06-13 Compugen Ltd. Bioactive peptides and method of using same
MX336145B (es) 2008-05-16 2016-01-08 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
WO2009140659A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating dyspnea associated with acute heart failure

Also Published As

Publication number Publication date
US20150320834A1 (en) 2015-11-12
NZ701038A (en) 2016-01-29
DK2288373T3 (en) 2015-09-28
TW200948353A (en) 2009-12-01
HK1139051A1 (en) 2010-09-10
MX2010012450A (es) 2011-03-21
HK1187550A1 (zh) 2014-04-11
PT2288373E (pt) 2015-10-19
US9205132B2 (en) 2015-12-08
US8053411B2 (en) 2011-11-08
US20130210730A1 (en) 2013-08-15
IL208992A (en) 2013-09-30
EP2829280A1 (en) 2015-01-28
JP2011520918A (ja) 2011-07-21
CN106177914A (zh) 2016-12-07
CN103212063B (zh) 2015-07-22
WO2009140659A3 (en) 2010-07-22
HUE025483T2 (en) 2016-02-29
GB2459983B (en) 2010-04-28
US20120040902A1 (en) 2012-02-16
HRP20150845T1 (hr) 2015-11-06
US20130116181A1 (en) 2013-05-09
IL228244A (en) 2016-10-31
US9579363B2 (en) 2017-02-28
US9066916B2 (en) 2015-06-30
HK1202054A1 (en) 2015-09-18
IL247351A0 (en) 2016-09-29
UA99953C2 (uk) 2012-10-25
CA2724540C (en) 2014-07-08
JP2016053040A (ja) 2016-04-14
MY158327A (en) 2016-09-30
CA2724540A1 (en) 2009-11-19
AU2009246114B2 (en) 2013-01-31
EA022948B1 (ru) 2016-03-31
BRPI0913011A2 (pt) 2019-09-03
WO2009140659A2 (en) 2009-11-19
TWI386202B (zh) 2013-02-21
PL2288373T3 (pl) 2015-11-30
AR071810A1 (es) 2010-07-14
GB0918132D0 (en) 2009-12-02
EP2288373A2 (en) 2011-03-02
NZ598709A (en) 2013-09-27
GB2459983A (en) 2009-11-18
JP2013040174A (ja) 2013-02-28
CR11749A (es) 2011-02-11
AU2009246114A1 (en) 2009-11-19
HK1151229A1 (en) 2012-01-27
IL208992A0 (en) 2011-01-31
GB2462221A (en) 2010-02-03
US8415301B2 (en) 2013-04-09
SG10201609580YA (en) 2016-12-29
US20120040903A1 (en) 2012-02-16
US20170151311A1 (en) 2017-06-01
JP5638044B2 (ja) 2014-12-10
GB0908432D0 (en) 2009-06-24
US8372809B2 (en) 2013-02-12
GB2462221B (en) 2010-09-01
EP2288373B1 (en) 2015-06-24
JP5651586B2 (ja) 2015-01-14
SG191587A1 (en) 2013-07-31
CN103212063A (zh) 2013-07-24
EA201500552A1 (ru) 2016-07-29
ES2546287T3 (es) 2015-09-22
JP2015013870A (ja) 2015-01-22
EA201001771A1 (ru) 2011-06-30
US20100048475A1 (en) 2010-02-25
MA32389B1 (fr) 2011-06-01
NZ589009A (en) 2012-05-25
HK1140693A1 (en) 2010-10-22
SI2288373T1 (sl) 2015-12-31
MY159803A (en) 2017-02-15
CN102036679A (zh) 2011-04-27
ZA201007449B (en) 2011-06-29
JP5875646B2 (ja) 2016-03-02

Similar Documents

Publication Publication Date Title
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
NZ800220A (en) Methods of treating heart failure by administering omecamtiv mecarbil
CY1121041T1 (el) Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης
EA201500552A1 (ru) Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
MX391565B (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
EA201991014A1 (ru) Лечение диабета
ZA201804696B (en) Therapeutic use of inhibitors of t cell activation or stimulation
EP3825419A3 (en) Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
PH12017500392A1 (en) Medical treatments based on anamorelin
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
EA201200319A1 (ru) Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана
UY31499A1 (es) Nuevo uso medico de las sales de propionato 3- (2,2,2-trimetilhydrazinio) en el trtamiento de la enfermedad cardiaca isquemica
WO2013177478A3 (en) Treatment method
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
RU2010154218A (ru) Способ лечения поздней кожной порфирии у больного зависимого от гемодиализа
UA109904C2 (uk) Комбінована терапія для шкірних розладів
UA49089U (ru) Способ лечения острой сердечной недостаточности